Nedosiran sodium
As of the edition of 20 October 2026, Nedosiran sodium is an oligonucleotide: marketed, first approved in 2023 (US); acts on ASGR1, ASGR2 and LDHA; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Oligonucleotide
- Brand name
- Rivfloza
- First approved
- 29 September 2023 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Novo Nordisk
- Registered trials
- 5, 0 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Nutrition and metabolism
US protection
US protection ends in 2038.
The last listed US drug-substance patent ends in 2038. The application that gives this date is held by Novo Nordisk.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product30 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 30 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Nedosiran sodium.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Originator and Lead sponsor of trials | 2017 to now |